Stock Evaluator: PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech, Inc. PMCB

$0.58 -0.02 -4.00%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 155,529
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company’s cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Commentary & Analysis


Financial Summary

Share Statistics PMCB Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $6.2 $252.6 5%
Shares Out (Mil) 10.7 52.3 21%
Institutional Ownership 58.1% 92.1% 38%
Float (Mil) 10.0 40.2 19%
Beta na 0.95 na
Avg Daily Volume (000s) 164 455 42%
Price Change
(52-week)
(43.8%) 52.9% 18%
Growth PMCB Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (40.1%) (9.9%) 9%
EPS (5yr) (2.5%) 16.0% 27
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (14.6%) (15.6%) 55%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials PMCB Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $38 na
Net Income (TTM) (Mil) ($19) ($43) 24%
EPS (TTM) ($2.770) ($1.600) 12%
Operating Cash Flow (TTM) (Mil) ($5) ($31) 24%
Net Cash Flow (TTM) (Mil) na $5 na
Long-Term Debt (Q1) (Mil) $0 $5 0%
Enterprise Value (Q1) (Mil) ($30) $180 1%
Valuation PMCB Industry
Median
Percentile
(All Stocks)
P/B 0.18 2.56 3%
P/E na 19.0 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.9 na
Ratios PMCB Industry
Median
Percentile
(All Stocks)
Gross Margin na 63.8% na
Net Margin na (67.3%) na
ROA (38.1%) (49.8%) 14%
ROE (45.4%) (55.5%) 16%
Liabilities to Assets 25.2% 30.3% 17%
F-Score 1 3 1%

Passing Stock Screens

As of 7/31/2026, from a list of 60 stock screening strategies, PMCB meetings the criteria of 1 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors